Janus Henderson Group PLC Sells 82,739 Shares of NewAmsterdam Pharma Company N.V. $NAMS

Janus Henderson Group PLC lowered its stake in shares of NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS) by 3.5% during the 1st quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 2,258,984 shares of the company’s stock after selling 82,739 shares during the quarter. Janus Henderson Group PLC’s holdings in NewAmsterdam Pharma were worth $72,254,000 at the end of the most recent quarter.

A number of other hedge funds also recently made changes to their positions in NAMS. Duquesne Family Office LLC grew its position in NewAmsterdam Pharma by 131.2% in the third quarter. Duquesne Family Office LLC now owns 1,923,700 shares of the company’s stock worth $54,710,000 after acquiring an additional 1,091,525 shares in the last quarter. Castle Hook Partners LP bought a new stake in NewAmsterdam Pharma during the fourth quarter worth about $38,062,000. Adage Capital Partners GP L.L.C. boosted its holdings in shares of NewAmsterdam Pharma by 54.5% in the 2nd quarter. Adage Capital Partners GP L.L.C. now owns 3,013,009 shares of the company’s stock worth $54,566,000 after purchasing an additional 1,062,359 shares in the last quarter. Goldman Sachs Group Inc. increased its position in shares of NewAmsterdam Pharma by 96.0% during the 4th quarter. Goldman Sachs Group Inc. now owns 1,725,662 shares of the company’s stock valued at $60,536,000 after purchasing an additional 845,110 shares during the last quarter. Finally, Wellington Management Group LLP increased its position in shares of NewAmsterdam Pharma by 21.0% during the 3rd quarter. Wellington Management Group LLP now owns 4,020,126 shares of the company’s stock valued at $114,332,000 after purchasing an additional 697,129 shares during the last quarter. 89.89% of the stock is owned by institutional investors.

NewAmsterdam Pharma Trading Down 2.4%

NAMS opened at $27.79 on Friday. NewAmsterdam Pharma Company N.V. has a 12 month low of $21.14 and a 12 month high of $42.21. The business’s 50-day moving average price is $32.16 and its 200-day moving average price is $32.65. The company has a market cap of $3.25 billion, a P/E ratio of -15.53 and a beta of 0.08.

NewAmsterdam Pharma (NASDAQ:NAMS) last issued its earnings results on Tuesday, March 31st. The company reported ($0.40) earnings per share for the quarter. NewAmsterdam Pharma had a negative net margin of 943.23% and a negative return on equity of 26.49%. The company had revenue of $3.04 million for the quarter. Equities research analysts forecast that NewAmsterdam Pharma Company N.V. will post -1.78 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other NewAmsterdam Pharma news, CAO Louise Frederika Kooij sold 105,000 shares of the business’s stock in a transaction that occurred on Monday, July 20th. The stock was sold at an average price of $30.34, for a total value of $3,185,700.00. Following the completion of the sale, the chief accounting officer owned 24,353 shares in the company, valued at approximately $738,870.02. The trade was a 81.17% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Insiders sold a total of 210,000 shares of company stock valued at $6,713,550 in the last ninety days. Insiders own 12.74% of the company’s stock.

Analyst Ratings Changes

A number of research firms recently weighed in on NAMS. Wall Street Zen upgraded NewAmsterdam Pharma from a “sell” rating to a “hold” rating in a research report on Saturday, May 9th. BMO Capital Markets started coverage on shares of NewAmsterdam Pharma in a research report on Monday, July 20th. They set an “outperform” rating and a $58.00 price target on the stock. Weiss Ratings reissued a “sell (d-)” rating on shares of NewAmsterdam Pharma in a research note on Friday, July 17th. Royal Bank Of Canada boosted their price objective on shares of NewAmsterdam Pharma from $47.00 to $51.00 and gave the stock an “outperform” rating in a report on Tuesday, June 30th. Finally, Jefferies Financial Group reaffirmed a “buy” rating and issued a $45.00 price objective on shares of NewAmsterdam Pharma in a research note on Monday, July 20th. Two analysts have rated the stock with a Strong Buy rating, ten have given a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $49.42.

About NewAmsterdam Pharma

NewAmsterdam Pharma, Inc is a clinical‐stage biopharmaceutical company focused on discovering and developing novel small‐molecule therapies for cardiometabolic diseases. The company’s research efforts are aimed at addressing key unmet needs in metabolic syndrome, obesity and type 2 diabetes by modulating pathways involved in glucose regulation, energy homeostasis and lipid metabolism.

The company’s development pipeline features multiple small‐molecule candidates at various stages of preclinical and clinical evaluation.